S&P 500   3,978.27 (+0.18%)
DOW   32,447.92 (+0.65%)
QQQ   308.36 (-0.81%)
AAPL   158.26 (-1.24%)
MSFT   276.44 (-1.47%)
META   202.11 (-1.89%)
GOOGL   102.66 (-2.64%)
AMZN   97.29 (-0.86%)
TSLA   190.59 (+0.09%)
NVDA   264.50 (-1.23%)
NIO   8.90 (-1.87%)
BABA   85.60 (-1.50%)
AMD   95.74 (-2.26%)
T   18.87 (+1.40%)
F   11.51 (+0.00%)
MU   59.65 (-2.47%)
CGC   1.89 (-0.71%)
GE   93.10 (+1.89%)
DIS   94.93 (+0.90%)
AMC   4.36 (-2.46%)
PYPL   73.40 (-0.65%)
PFE   40.31 (-0.20%)
NFLX   326.89 (-0.46%)
S&P 500   3,978.27 (+0.18%)
DOW   32,447.92 (+0.65%)
QQQ   308.36 (-0.81%)
AAPL   158.26 (-1.24%)
MSFT   276.44 (-1.47%)
META   202.11 (-1.89%)
GOOGL   102.66 (-2.64%)
AMZN   97.29 (-0.86%)
TSLA   190.59 (+0.09%)
NVDA   264.50 (-1.23%)
NIO   8.90 (-1.87%)
BABA   85.60 (-1.50%)
AMD   95.74 (-2.26%)
T   18.87 (+1.40%)
F   11.51 (+0.00%)
MU   59.65 (-2.47%)
CGC   1.89 (-0.71%)
GE   93.10 (+1.89%)
DIS   94.93 (+0.90%)
AMC   4.36 (-2.46%)
PYPL   73.40 (-0.65%)
PFE   40.31 (-0.20%)
NFLX   326.89 (-0.46%)
S&P 500   3,978.27 (+0.18%)
DOW   32,447.92 (+0.65%)
QQQ   308.36 (-0.81%)
AAPL   158.26 (-1.24%)
MSFT   276.44 (-1.47%)
META   202.11 (-1.89%)
GOOGL   102.66 (-2.64%)
AMZN   97.29 (-0.86%)
TSLA   190.59 (+0.09%)
NVDA   264.50 (-1.23%)
NIO   8.90 (-1.87%)
BABA   85.60 (-1.50%)
AMD   95.74 (-2.26%)
T   18.87 (+1.40%)
F   11.51 (+0.00%)
MU   59.65 (-2.47%)
CGC   1.89 (-0.71%)
GE   93.10 (+1.89%)
DIS   94.93 (+0.90%)
AMC   4.36 (-2.46%)
PYPL   73.40 (-0.65%)
PFE   40.31 (-0.20%)
NFLX   326.89 (-0.46%)
S&P 500   3,978.27 (+0.18%)
DOW   32,447.92 (+0.65%)
QQQ   308.36 (-0.81%)
AAPL   158.26 (-1.24%)
MSFT   276.44 (-1.47%)
META   202.11 (-1.89%)
GOOGL   102.66 (-2.64%)
AMZN   97.29 (-0.86%)
TSLA   190.59 (+0.09%)
NVDA   264.50 (-1.23%)
NIO   8.90 (-1.87%)
BABA   85.60 (-1.50%)
AMD   95.74 (-2.26%)
T   18.87 (+1.40%)
F   11.51 (+0.00%)
MU   59.65 (-2.47%)
CGC   1.89 (-0.71%)
GE   93.10 (+1.89%)
DIS   94.93 (+0.90%)
AMC   4.36 (-2.46%)
PYPL   73.40 (-0.65%)
PFE   40.31 (-0.20%)
NFLX   326.89 (-0.46%)
Positive News Sentiment  
NASDAQ:ALDX

Aldeyra Therapeutics - ALDX Stock Forecast, Price & News

$8.63
-0.40 (-4.43%)
(As of 03/27/2023 12:46 PM ET)
Add
Compare
Today's Range
$8.41
▼
$9.00
50-Day Range
$5.77
▼
$9.06
52-Week Range
$2.36
▼
$9.20
Volume
808,022 shs
Average Volume
495,090 shs
Market Capitalization
$505.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

Aldeyra Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
137.8% Upside
$20.50 Price Target
Short Interest
Bearish
3.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.35) to ($1.42) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

378th out of 995 stocks

Pharmaceutical Preparations Industry

171st out of 482 stocks

See Top Rated MarketRank™ Stocks Here

ALDX stock logo

About Aldeyra Therapeutics (NASDAQ:ALDX) Stock

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALDX Stock News Headlines

March 18, 2023 | americanbankingnews.com
Aldeyra Therapeutics (NASDAQ:ALDX) Now Covered by StockNews.com
March 11, 2023 | finance.yahoo.com
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2022 Earnings Call Transcript
March 27, 2023 | UNKNOWN (Ad)
The Value Of This Metal Is Going Unnoticed By Wall St.
This Stock Could Be Undervalued Considering The Race For Renewable Energy Is Here!pixel
March 10, 2023 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Aldeyra Therapeutics (ALDX)
March 10, 2023 | finance.yahoo.com
Q4 2022 Aldeyra Therapeutics Inc Earnings Call
March 9, 2023 | msn.com
Aldeyra Therapeutics GAAP EPS of -$1.06 beats by $0.10
March 9, 2023 | finance.yahoo.com
Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
March 8, 2023 | msn.com
Aldeyra Therapeutics Q4 2022 Earnings Preview
March 27, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
March 8, 2023 | msn.com
Earnings Outlook For Aldeyra Therapeutics
March 3, 2023 | markets.businessinsider.com
SVB Securities Keeps Their Buy Rating on Aldeyra Therapeutics (ALDX)
March 2, 2023 | marketwatch.com
Aldeyra Gets FDA Priority Review for ADX-2191 in Rare Retinal Cancer >ALDX
March 2, 2023 | finance.yahoo.com
FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma
March 1, 2023 | finance.yahoo.com
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights
February 28, 2023 | finance.yahoo.com
Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease
February 23, 2023 | finance.yahoo.com
Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy
February 22, 2023 | finance.yahoo.com
Owning 40% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX),
February 16, 2023 | finance.yahoo.com
Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease Trials
February 9, 2023 | finance.yahoo.com
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
February 7, 2023 | finance.yahoo.com
Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease
January 12, 2023 | finance.yahoo.com
Insiders made the right call by buying US$1.2m Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) stock this year, currently sit on US$349k profit
December 21, 2022 | msn.com
Aldeyra files for FDA approval of ADX‑2191 for rare eye cancer
December 21, 2022 | markets.businessinsider.com
Aldeyra Therapeutics Submits NDA For ADX-2191
December 21, 2022 | finance.yahoo.com
Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication
December 21, 2022 | finance.yahoo.com
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma
December 14, 2022 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: Masimo (MASI), Aldeyra Therapeutics (ALDX)
December 13, 2022 | finance.yahoo.com
Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial
See More Headlines
Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALDX Company Calendar

Last Earnings
10/27/2021
Today
3/27/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALDX
CUSIP
N/A
CIK
1341235
Web
www.ampliphibio.com
Phone
781-761-4904
Fax
781-270-0630
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.50
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+99.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-62,030,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-36.60%
Return on Assets
-31.22%

Debt

Debt-to-Equity Ratio
0.10
Current Ratio
11.78
Quick Ratio
11.78

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.58 per share
Price / Book
3.50

Miscellaneous

Outstanding Shares
58,580,000
Free Float
54,476,000
Market Cap
$528.98 million
Optionable
Optionable
Beta
1.07

Key Executives

  • Todd C. Brady (Age 48)
    M.D., Ph.D., Chief Executive Officer and Director
  • Joshua Reed (Age 47)
    Chief Financial Officer
  • David McMullin (Age 45)
    Chief Commercial Officer
  • James A. Gow (Age 53)
    M.D., Senior Vice President of Clinical Development
  • Stephen G. Machatha (Age 43)
    Ph.D., Senior Vice President, Technical Operation

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ALDX Stock - Frequently Asked Questions

Should I buy or sell Aldeyra Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALDX shares.
View ALDX analyst ratings or view top-rated stocks.

What is Aldeyra Therapeutics' stock price forecast for 2023?

3 brokerages have issued 1 year price objectives for Aldeyra Therapeutics' stock. Their ALDX share price forecasts range from $11.00 to $28.00. On average, they predict the company's share price to reach $20.50 in the next year. This suggests a possible upside of 123.3% from the stock's current price.
View analysts price targets for ALDX or view top-rated stocks among Wall Street analysts.

How have ALDX shares performed in 2023?

Aldeyra Therapeutics' stock was trading at $6.96 at the start of the year. Since then, ALDX stock has increased by 31.9% and is now trading at $9.18.
View the best growth stocks for 2023 here.

When is Aldeyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ALDX earnings forecast.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) issued its earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.01. During the same period in the prior year, the business earned ($0.23) EPS.

What ETFs hold Aldeyra Therapeutics' stock?

ETFs with the largest weight of Aldeyra Therapeutics (NASDAQ:ALDX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Invesco DWA SmallCap Momentum ETF (DWAS) and ALPS Medical Breakthroughs ETF (SBIO),

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Eagle Asset Management Inc. (3.03%), Verition Fund Management LLC (2.66%), Dimensional Fund Advisors LP (1.52%), Millennium Management LLC (1.45%), Geode Capital Management LLC (0.80%) and Two Sigma Investments LP (0.77%). Insiders that own company stock include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc and Todd C Brady.
View institutional ownership trends.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $9.18.

How much money does Aldeyra Therapeutics make?

Aldeyra Therapeutics (NASDAQ:ALDX) has a market capitalization of $537.76 million. The biotechnology company earns $-62,030,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The official website for the company is www.ampliphibio.com. The biotechnology company can be reached via phone at 781-761-4904, via email at ir@ampliphibio.com, or via fax at 781-270-0630.

This page (NASDAQ:ALDX) was last updated on 3/27/2023 by MarketBeat.com Staff